Patent intelligence · AU
AU 2025242171
A Medicament and Method of Treatment of Central Nervous System and/or Neuropsychiatric Disorders
A Medicament and Method of Treatment of Central Nervous System and/or Neuropsychiatric Disorders
Patent details — AU 2025242171
- Jurisdiction
- AU
- Status
- granted
- Grant date
- Dec 11, 2025
- Expiration
- Dec 6, 2045
- Applicant
- BEIGENE SWITZERLAND GMBH [CH]
- CPC classes
- A61K 9/ 08 A I, A61K 31/ 439 A I, A61K 31/ 4439 A I, A61K/31439
Quick answer
AU 2025242171 (A Medicament and Method of Treatment of Central Nervous System and/or Neuropsychiatric Disorders) is held by BEIGENE SWITZERLAND GMBH [CH]. Status: granted. Granted Dec 11, 2025. Expires Dec 6, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- BEIGENE SWITZERLAND GMBH [CH]
- Grant date
- Expiration
- Claims
- —
- CPC classes
- A61K 9/ 08 A I, A61K 31/ 439 A I, A61K 31/ 4439 A I, A61K/31439, A61K/314439, A61K/90043
More from BEIGENE SWITZERLAND GMBH [CH]
Related pharmaceutical patents in our USPTO index.
-
WO 2025252204
DISPERSIONS SOLIDES AMORPHES D'UN INHIBITEUR DE BRAF
granted -
WO 2025232885
PROCÉDÉ DE PRÉPARATION D'UN AGENT DE DÉGRADATION DE LA TYROSINE KINASE DE BRUTON
granted -
WO 2025218772
FORMES SOLIDES COMPRENANT UN AGENT DE DÉGRADATION DE TYROSINE KINASE DE BRUTON ET LEURS UTILISATIONS
granted -
WO 2025214466
CONJUGUÉS DE PYRROLOBENZODIAZÉPINE CIBLÉS
granted -
WO 2025201453
COMPOSÉS MACROCYCLIQUES UTILISÉS EN TANT QU'INHIBITEURS DE RAS
granted -
US 2025304535
KAT6 Inhibitors
granted -
US 2025290040
GAMMA DELTA T CELL COMPOSITIONS AND METHODS OF USE
granted
Frequently asked questions
What is US patent 2025242171?
AU 2025242171 (A Medicament and Method of Treatment of Central Nervous System and/or Neuropsychiatric Disorders) is held by BEIGENE SWITZERLAND GMBH [CH]. Status: granted. Granted Dec 11, 2025. Expires Dec 6, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Who owns AU 2025242171?
BEIGENE SWITZERLAND GMBH [CH] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 25 pharmaceutical patents for this assignee.
When does AU 2025242171 expire?
Our index shows an expiration date of Dec 6, 2045 (19 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.